Arsene-bienvenu B. Loembe
Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.
Journal: British journal of cancer
Published: September 15, 2025
IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors.
Journal: Cancer research communications
Published: July 10, 2025
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
Journal: Journal for immunotherapy of cancer
Published: May 25, 2022
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 28, 2021
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 20, 2021
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 16, 2017
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma.
Journal: Liver cancer
Published: August 09, 2017
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: August 02, 2016
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.
Journal: Investigational new drugs
Published: January 16, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026